Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 3Sarcoma 1Genitourinary 1Gastrointestinal 1Endocrine 1Dermatologic 1CNS 1Breast 1

Conditions

Glioblastoma 4Glioma 3Breast Neoplasms 3Brain Neoplasms 3Cholangiocarcinoma 2Central Nervous System Neoplasms 2Thyroid Neoplasms 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Meningeal Carcinomatosis 1Melanoma 1Lymphoma 1Colonic Neoplasms 1Chondrosarcoma 1

Interventions

Magnetic Resonance Spectroscopy 6Specimen Handling 3Nivolumab 3Fluorodeoxyglucose F18 3Cisplatin 3Cetuximab 3ulixertinib 2tipifarnib 2selpercatinib 2binimetinib 2Trastuzumab 2Surveys and Questionnaires 2Radiotherapy 2Paclitaxel 2Immunoglobulin G 2Gemcitabine 2FAPI-46 2Disulfides 2Biopsy 2vandetanib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1trastuzumab biosimilar HLX02 1trametinib 1temsirolimus 1sargramostim 1sapanisertib 1romidepsin 1relatlimab 1pertuzumab 1pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid Neoplasms × durvalumab × CNS × Clear all
NCT04521686 2026-04-22

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

Eli Lilly and Company

Phase 1 Active not recruiting
200 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryHead & NeckSarcoma

Breast Neoplasms, Chondrosarcoma, Colonic Neoplasms, Glioblastoma, Glioma, Melanoma, Prostatic Neoplasms, Thyroid Neoplasms, Central Nervous System Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡